PRELIMINARY PROGRAM 2024

Monday 29/04

09:00
Registration & Poster Exhibition

The poster exhibition will be open all day.

09:20 - 09:30
Welcome and Opening Remarks

Dr Christian Stein & Rebecca Engels, Ascenion

09:30 - 10:40
Presentation Stream 1: Inflammation & Immune Response

Chair: Dr Stefanie Possekel, Ascenion

--

Johnson & Johnson Innovation: Accelerating breakthrough innovations in healthcare
Dr Ralf Angermund, Director Early Innovation Partnering Germany, Johnson & Johnson Innovation

A7
Novel Diagnostic for Liver Diseases
Dr Richard Taubert, Hannover Medical School
H1
TUBiRA: Lead Optimization of First-in-Class TRAF6-Ubc13 Inhibitors for Treatment of Rheumatoid Arthritis
Dr Kamyar Hadian, Helmholtz Munich
I2
PX, a Selective, Alternative Pathway Inhibitor for Treatment of Complement Dysregulation Diseases
Hagen Sülzen, IOCB Prague
C1
A Novel Small Molecule for Treatment of Non-Histaminergic and Chronic Itch
Prof. Achim Schmidtko, Goethe University Frankfurt/Main
W1
Single-Domain Antibody Inhibiting Neutrophil Elastase for the Treatment of Inflammatory Lung Diseases
Dr Mireille Dumoulin, University of Liège
10:40 - 11:00
Networking & Poster Session
11:00 - 12:00
Startup Pitches

Chair: Dr Sören Rindfleisch, Ascenion


Emerging
 

  • Atheon Bio
  • Epitome Therapeutics
  • Promental Health
  • Quasar Therapeutics
  • RNhale GmbH

 

 

Rising
 

  • CapCo Bio GmbH
  • CureVision GmbH
  • Genome Biologics GmbH
  • SeaBeLife Biotech
  • SurvivX B.V.
12:00 - 13:00
Early-Stage Innovations (GO-Bio initial & ForTra Pitches)

Chair: Rebecca Engels, Ascenion

13:00 - 14:00
Lunch & Networking
14:00 - 14:30
Meet the Partners
14:30 - 16:00
Presentation Stream 2: Infection & Vaccines

Chair: Dr Stefan Scherer, Helmholtz Centre for Infection Research (HZI)

--

Introducing MAxL - Munich Accelerator Life Sciences & Medicine
Regina Abendroth, Program & Community Manager MAxL, BioM

A1
Overcoming Resistance - Novel Inhibitors of Virulence Factor LasB of Pseudomonas aeruginosa
Dr Jörg Haupenthal, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)
B3
New Antimicrobial Peptide against Antibiotic Resistant Bacteria
Dr Sigrid Bülow, University of Regensburg
E3
Novel Drug Combinations to Fight Multi-Resistant Bacteria and Prevent Antibiotic Damage on the Gut Microbiome
Dr Julia Dieter, EMBLEM Technology Transfer GmbH
H3
Novel Therapeutics to Tackle the STI Crisis (Focus: Neisseria gonorrhoeae)
Dr Katarina Cirnski, Helmholtz Centre for Infection Research (HZI) & Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)
A2
Novel Inhibitors of Cytomegalovirus
Prof. Mark Brönstrup, Helmholtz Centre for Infection Research
W2
New TMPRSS2 Inhibitors as Antivirals for Coronavirus and Influenza Pandemics
Dr Pierre Francotte, University of Liège
M1
A Novel Platform for Mucosally-Applied Vaccines Against Respiratory Viruses
Dr Marian Wiegand, Helmholtz Munich
A4
Efficient, Adjuvant-Free Mucosal Vaccination via IgA Feedback Loop
Dr Andreas Frey, Research Center Borstel - Leibniz Lung Center
16:00 - 16:30
Networking & Poster Session
16:30 - 17:30
Presentation Stream 3: Oncology

Chair: Dr Jürgen Walkenhorst, PROvendis

--

Partnering with AbbVie
Dr Joachim Vogt, Director Search & Evaluation Western Europe, AbbVie

E5
Method for ENO1-Based Compound Screening to Modulate Glycolysis in Cancer Cells
Dr Laurène Ramos Martins, EMBL Heidelberg
M3
Generation of an Antibody Directed Against CCL22 for Cancer Immunotherapy
Cansu Pala Cetiner, Lead Discovery Center
I3
Chemically Engineered NK Cells for Cancer Immunotherapy
Dr Milan Vrabel, IOCB Prague
A5
TCR/CD3-Specific CAR NK-92 Cells for Purification of TCR-Modified Cell Products 
Jonas Kath, Charité - Universitätsmedizin Berlin
A8
Arming Oncolytic Viruses Using Membrane-Associated T-Cell Activators (MATEs)
Prof. Florian Kühnel, Hannover Medical School
17:30 - 18:00
Networking & Poster Session
18:00
Evening Reception at the Augustiner Keller

Tuesday 30/04

09:00
Registration & Networking
09:30 - 10:30
Presentation Stream 4: Vascular System & Patient Care

Chair: Dr Laura Spinardi, FITT

H5
TRYPTO Therapeutics Develops a Novel Class of Tryptophan Hydroxylase-1 Inhibitors to Address Unmet Medical Needs in Serotonin-Dependent Diseases
Dr Dirk Pleimes, TRYPTO Therapeutics
E2
Novel Autotaxin Inhibitors
Dr Mathias Eymery, EMBL Grenoble
P1
Extracorporeal Apheresis to Treat Preeclampsia
Dr Jürgen Walkenhorst, PROvendis GmbH
F3
Vascular Simulation Device for Medical Training in Eco-guided Procedures
Dr Valeria Mauri, Fondazione IRCCS Policlinico San Matteo
F4
Highly Personalized Non-Invasive Vagus Nerve Stimulation for the Treatment of Chronic Pain
Dr Angelica Carandina, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico/Università degli Studi di Milano
F1
Protective Device for Subjects with Solitary Kidney or Kidney Disease
Dr Filippo Spreafico, Fondazione IRCCS Istituto Nazionale dei Tumori
10:30 - 11:00
Networking & Poster Session
11:00 - 12:00
External Lecture - Evolution and patenting of AI in MedTech

Carlos Rivera Pons, Team Manager Healthcare Informatics, EPO

12:00 - 13:30
Lunch & Networking
13:30 - 13:40
Startup & Early-Stage Innovation Award Ceremony
13:40 - 14:40
Presentation Stream 5: Neurodegeneration, Biomarkers & Drug Delivery

Chair: Dr Juliane Proft, IOCB-TECH

--

MSD Business Development & Licensing - Invent with Us
Dr Richard Reschen, Director BD & L Europe, MSD

I6
New Treatment for Glaucoma
Prof. Andrea Brancale, University of Chemistry and Technology, Prague
P2
Anti-KLK8 against Alzheimer’s disease
Prof. Kathy Keyvani, University of Duisburg-Essen
F5
MicroRNAs as Diagnostic Biomarkers and Therapeutic Agents for Small Fiber Neuropathy
Dr Mirna Andelic, Fondazione IRCCS Istituto Neurologico Carlo Besta
I5
Coelenterazine-Utilizing Luciferase Reporters with Extremely Stable Glow-Type Bioluminescent Signal
Dr Martin Marek, Masaryk University
A3
Biodynamers Enhance Drug Delivery
Prof. Sangeun Lee, Saarland University
14:40
Networking & Poster Session / Closing Reception